Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Swedberg

Showing results (331-340 of 471) with videos related to

Pageof 48
Sort By:
Journal of Cardiac Failure|February 11, 2005
Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot studyMilton Packer, John McMurray, Barry M Massie, et al.
Circulation. Heart Failure|September 14, 2016
Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background TherapyNaoki Okumura, Pardeep S Jhund, Jianjian Gong, et al.
European Heart Journal|March 21, 2023
Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradoxJawad H Butt, Mark C Petrie, Pardeep S Jhund, et al.
European Heart Journal|May 5, 2009
Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trialJohn E A Blair, Sadiya Khan, Marvin A Konstam, et al.
International Journal of Cardiology|November 6, 2012
The past, present and future of renin-angiotensin aldosterone system inhibitionRobert J Mentz, George L Bakris, Bernard Waeber, et al.
JAMA Cardiology|August 30, 2024
Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure: Post Hoc Analysis of the PARADIGM-HF and PARAGON-HF Randomized Clinical TrialsHenri Lu, Brian L Claggett, Milton Packer, et al.
European Journal of Heart Failure|January 16, 2007
Prevalence of ECG abnormalities in an international survey of patients with suspected or confirmed heart failure at death or dischargeNasrin K Khan, Kevin M Goode, John G F Cleland, et al.
European Heart Journal|June 7, 2006
Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programmeJohn J V McMurray, Fredrik L Andersson, Simon Stewart, et al.
Journal of the American College of Cardiology|November 13, 2007
Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM ProgramAkshay S Desai, Karl Swedberg, John J V McMurray, et al.
Journal of the American College of Cardiology|November 11, 2008
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) programJohn E A Blair, Faiez Zannad, Marvin A Konstam, et al.
Pageof 48

Showing results (331-340 of 471) with videos related to

Sort By:
Pageof 48
Journal of Cardiac Failure|February 11, 2005
Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot studyMilton Packer, John McMurray, Barry M Massie, et al.
Circulation. Heart Failure|September 14, 2016
Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background TherapyNaoki Okumura, Pardeep S Jhund, Jianjian Gong, et al.
European Heart Journal|March 21, 2023
Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradoxJawad H Butt, Mark C Petrie, Pardeep S Jhund, et al.
European Heart Journal|May 5, 2009
Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trialJohn E A Blair, Sadiya Khan, Marvin A Konstam, et al.
International Journal of Cardiology|November 6, 2012
The past, present and future of renin-angiotensin aldosterone system inhibitionRobert J Mentz, George L Bakris, Bernard Waeber, et al.
JAMA Cardiology|August 30, 2024
Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure: Post Hoc Analysis of the PARADIGM-HF and PARAGON-HF Randomized Clinical TrialsHenri Lu, Brian L Claggett, Milton Packer, et al.
European Journal of Heart Failure|January 16, 2007
Prevalence of ECG abnormalities in an international survey of patients with suspected or confirmed heart failure at death or dischargeNasrin K Khan, Kevin M Goode, John G F Cleland, et al.
European Heart Journal|June 7, 2006
Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programmeJohn J V McMurray, Fredrik L Andersson, Simon Stewart, et al.
Journal of the American College of Cardiology|November 13, 2007
Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM ProgramAkshay S Desai, Karl Swedberg, John J V McMurray, et al.
Journal of the American College of Cardiology|November 11, 2008
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) programJohn E A Blair, Faiez Zannad, Marvin A Konstam, et al.
Pageof 48